Niina Ayaka, Kibe Ryoko, Suzuki Ryohei, Yuchi Yunosuke, Teshima Takahiro, Matsumoto Hirotaka, Kataoka Yasushi, Koyama Hidekazu
Laboratory of Veterinary Internal Medicine, School of Veterinary Medicine, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino, Tokyo, Japan.
Laboratory of Veterinary Microbiology, School of Veterinary Medicine, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino, Tokyo, Japan.
Vet Med (Auckl). 2019 Dec 2;10:197-201. doi: 10.2147/VMRR.S230862. eCollection 2019.
Recently, fecal microbiota transplantation (FMT) has been tested in veterinary medicine as a treatment option for multiple gastrointestinal (GI) diseases, such as inflammatory bowel disease (IBD). However, there are no reports of changes in the microbial diversity of fecal microbiome after treatment with FMT in canine IBD cases. Moreover, little is known about the long-term efficacy and safety of FMT treatment for dogs. Herein, we present a case of canine intractable IBD treated with repeated, long-term FMT.
The patient was a 10-year-old, neutered, male, 4-kg Toy Poodle with a prolonged history of vomiting and diarrhea. Fecal examination for pathogens was negative. Despite treatment with multiple antibacterial and antidiarrheal agents, the patient showed no improvement. Endoscopic mucus sampling diagnosed a case of lymphocytic-plasmacytic duodenitis, ie, idiopathic IBD. Eventually, we performed periodic, long-term fecal microbiota transplantation of fresh donor feces collected from a 4-year-old, 32.8-kg, neutered male Golden Retriever by rectal enema. Additionally, we performed 16S rRNA sequence analysis, before and after FMT, to evaluate the microbiome diversity.
Fecal microbiome diversity after FMT resembled that of the healthy donor dog's fecal microbiome, before FMT, which led us to conclude that the fecal microbiome in our patient normalized with FMT. Moreover, the clinical symptoms improved remarkably with regard to the changes in the fecal microbiome. Additionally, we noted no observable side effects during FMT treatment.
This report indicates the efficacy and safety of long-term, periodic FMT for a case of canine IBD based on attenuation of clinical symptoms and changes in fecal microbiome diversity. Therefore, FMT could be chosen as a treatment option for IBD in canines in the future.
最近,粪便微生物群移植(FMT)已在兽医学中作为多种胃肠道(GI)疾病(如炎症性肠病(IBD))的一种治疗选择进行了测试。然而,在犬IBD病例中,尚无关于FMT治疗后粪便微生物组微生物多样性变化的报道。此外,对于犬FMT治疗的长期疗效和安全性知之甚少。在此,我们报告一例经反复、长期FMT治疗的犬难治性IBD病例。
该患者为一只10岁、已绝育的4千克雄性玩具贵宾犬,有长期呕吐和腹泻病史。粪便病原体检查为阴性。尽管使用了多种抗菌和止泻药物治疗,患者仍无改善。内镜下黏液取样诊断为淋巴细胞-浆细胞性十二指肠炎症,即特发性IBD。最终,我们通过直肠灌肠对从一只4岁、32.8千克、已绝育的雄性金毛寻回犬收集的新鲜供体粪便进行了定期、长期的粪便微生物群移植。此外,我们在FMT前后进行了16S rRNA序列分析,以评估微生物组多样性。
FMT后的粪便微生物组多样性与FMT前健康供体犬的粪便微生物组相似,这使我们得出结论,我们患者的粪便微生物组通过FMT恢复正常。此外,随着粪便微生物组的变化,临床症状显著改善。此外,我们在FMT治疗期间未观察到明显的副作用。
本报告表明,基于临床症状的减轻和粪便微生物组多样性的变化,长期、定期FMT对一例犬IBD有效且安全。因此,FMT将来可被选为犬IBD的一种治疗选择。